H epatitis C is a major public health concern of epidemic proportion. Several treatment protocols have achieved reasonably good results with interferon (IFN) alpha and ribavirin (1, 2) . However, research continues in an effort to identify a highly effective treatment with minimal side effects. Subcutaneous injection of IFNb is a relatively new therapy for hepatitis C virus (HCV) that has great potential (3) . Although generally safe (4, 5) , IFNb has been recognized to cause local skin irritation on occasion. More serious local complications have not been described. We report a case of fasciitis complicating IFNb injection.
CASE PRESENTATION
A 36-year-old HCV-infected man managed with daily subcutaneous IFNb injections presented with a four-day history of progressively worsening left anterior-lateral tight swelling, erythema and pain associated with a temperature of 38.8°C, a white blood cell count of 7.6x10 An ill-defined low density fluid collection measuring 5x3x8 cm was noted within the lateral aspect of the left tight in the region of the vastus lateralis. An additional collection was noted in the region of the tensor fascia lata extending to the lesser trochanter. Surgical exploration revealed small pockets of odourless, turbid fluid located between the fascial surfaces of healthy muscle. Frank pus was not observed.
Gram stain of the fluid revealed Gram-positive cocci in clumps subsequently cultured as Staphylococcus aureus sensitive to oxacillin (minimum inhibitory concentration [MIC] less than 0.5 m g/mL), cefazolin (MIC less than 2 m g/mL), gentamicin (MIC less than less than 1 m g/mL), tetracycline (MIC less than 2 m g/mL), trimethoprim-sulphamethoxazole (MIC less than 2/38 m g/mL), clindamycin (MIC less than 0.25 m g/mL) and vancomycin (MIC less than 2 m g/mL). Blood cultures were negative.
Intravenous cloxacillin 2 g every 6 h was administered for two weeks, followed by four weeks of oral cloxacillin 500 mg every 6 h for a diagnosis of S aureus fasciitis with compartment syndrome.
DISCUSSION
S aureus fasciitis following subcutaneous injection of IFNb is a previously unrecognized complication of this treatment modality. A MEDLINE search failed to identify documented bacterial or chemical fasciitis complicating subcutaneous IFN injection. The presence of S aureus in multiple surgical sites suggested against the diagnosis of chemical fasciitis with incidental culture contamination with skin organism. Culture of the powered IFN taken directly from the vial and the sterile normal saline used to reconstitute the IFN did not yield S aureus, thereby ruling out injection product contamination. We postulate that S aureus was introduced into the fascial plane as a result of poor cutaneous preparation of the injection site before injection. This was admitted by the patient. No further injection site complications were encountered in this patient following enforcement of strict hygienic measures including pre-administration showering and thorough cleaning with alcohol before injection.
A review of the 65 patients who have received IFNa and IFNb injections as part of clinical trials at our centre over the past eight years revealed no major life-threatening complications. No cases of deep structure infection such as bacterial fasciitis were identified; however, nine patients (13.8%) developed erythema in the region of the injection, which resolved with discontinuation of the injections.
We have noted several potential risk factors for the development of local erythema including being female, dermal disease, sun exposure, venous insufficiency and failure to inject the medication deep enough. Reactions were more frequent in the first month of injections and in patients injecting daily versus those injecting three times weekly. Given the small numbers no statistically significant association could be identified.
CONCLUSIONS
We recommend as standard practice showering immediately before injection to avoid injection site infection. As with all subcutaneous injections, the area must be thoroughly disinfected with alcohol pads. Additionally, we advise patients to avoid pimples and cuts in the injection site. These simple precautions will avoid interruption in IFN therapy and prevent serious complications such as the one described above.
